Please provide your email address to receive an email when new articles are posted on . Treatment with any immune checkpoint inhibitor increased venous thromboembolism risk for adults with metastatic ...

Among propensity-matched cohorts, 17% of patients with metastatic lung cancer who received ICIs developed a pulmonary embolism within 1 year of beginning treatment, compared with 14.6% of those who ...

China: Use of angiotensin receptor–neprilysin inhibitors (ARNIs) in lung cancer patients with hypertension receiving immune ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. We have a number of excellent frontline ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

Efficacy and safety of nivolumab plus chemotherapy versus chemotherapy alone for the treatment of advance non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled ...

A new editorial was published in Volume 12 of Oncoscience on May 2, 2025, titled "Immune checkpoint inhibitors and myocarditis: Lessons from a nationwide cohort study." In this editorial, Bishal ...

Accelerating advancements in cancer prevention and cures, a University of Houston pharmacologist has received a grant from ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...